SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 141.70 |
| Enterprise Value ($M) | 83.48 |
| Book Value ($M) | 243.03 |
| Book Value / Share | 4.50 |
| Price / Book | 0.58 |
| NCAV ($M) | 232.24 |
| NCAV / Share | 4.30 |
| Price / NCAV | 0.61 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.04 |
| Return on Assets (ROA) | -0.04 |
| Return on Equity (ROE) | -0.05 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 22.63 |
| Current Ratio | 22.63 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 249.92 |
| Assets | 260.72 |
| Liabilities | 17.68 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 80.00 |
| Operating Income | -19.83 |
| Net Income | -9.72 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -2.22 |
| Cash from Investing | 32.23 |
| Cash from Financing | 2.75 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Adage Capital Management, L.P. | 5.56 | ||
| 13G | Suvretta Capital Management, Llc | 6.30 | 187.85 | |
| 13G | BlackRock, Inc. | 10.30 | -2.30 | |
| 13G | Nantahala Capital Management, LLC | 7.66 | ||
| 13G/A | Rtw Investments, Lp | 0.00 | -100.00 | |
| 13G/A | Vanguard Group Inc | 5.24 | 0.00 | |
| 13G/A | Fmr Llc | 2.76 | -69.67 | |
| 13G | TCG Crossover GP II, LLC | 9.40 | ||
| 13G/A | Ra Capital Management, L.p. | 19.30 | 84.50 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 18,486 | 138,348 | 13.36 | |
| 50,175 | 203,444 | 24.66 | |
| 69,861 | 308,576 | 22.64 | |
| 57,861 | 359,539 | 16.09 | |
| 156,176 | 711,956 | 21.94 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| FATE – Fate Therapeutics, Inc. | FHTX – Foghorn Therapeutics Inc. |
| FOLD – Amicus Therapeutics, Inc. | GANX – Gain Therapeutics, Inc. |
| GHRS – GH Research PLC |
Financial data and stock pages provided by
Fintel.io